Back to Stocks

FLNA

FILANA THERAPEUTICS, INC.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Filana Therapeutics has undergone a fundamental operational transformation, pivoting from a broad neurodegeneration focus to a lean, catalyst-driven biotechnology company.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of a leaner operation, Filana's financial health remains precarious. While headline expenses have dropped, the company continues to generate significant net losses, and its $86.6 million cash balance is heavily offset by a $32.75 million litigation reserve.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every FLNA filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company in a high-stakes transition. Filana has successfully cleared the decks of its previous regulatory baggage and the financial weight of its failed Alzheimer's program, but it now faces a critical binary event: the lifting of the FDA clinical hold for its TSC-related epilepsy program. The financial results show a company that is effectively 'hibernating'—reducing costs to survive until it can restart clinical trials. For investors, the trade-off is clear. The downside is a continued burn of cash and potential dilution while waiting for regulatory clearance that may never come or may be delayed further. The upside is a first-in-class therapeutic for a significant unmet need in epilepsy. The synthesis of this filing suggests that while the operational 'cleanup' is complete, the fundamental value of the company now rests entirely on the FDA's willingness to allow simufilam to proceed into human trials for TSC.

Selected Quarter

Core Takeaway

The company has successfully reduced its quarterly burn and cleared past regulatory investigations, but its future depends on lifting an FDA clinical hold for its lead candidate.

Investor Lens

Investors must weigh the benefit of a lower burn rate against the risk of a prolonged FDA delay and existing legal liabilities.

Watch Next

FDA communication regarding the lifting of the clinical hold for the simufilam TSC-related epilepsy IND.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.13Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Significant reduction in R&D and G&A expenses following the phase-out of the Alzheimer's program.

margin expansion
70%
bearishMay 7

FDA placed the lead TSC-related epilepsy program on a full clinical hold.

regulatory action
90%
bullishMay 7

Formal closure of DOJ and SEC investigations into the company.

regulatory action
60%
bullishMay 7

Significant reduction in R&D and G&A expenses following the phase-out of the Alzheimer's program.

margin expansion
70%
bearishMay 7

FDA placed the lead TSC-related epilepsy program on a full clinical hold.

regulatory action
90%
bullishMay 7

Formal closure of DOJ and SEC investigations into the company.

regulatory action
60%
bullishMay 7

Significant reduction in R&D and G&A expenses following the phase-out of the Alzheimer's program.

margin expansion
70%
bearishMay 7

FDA placed the lead TSC-related epilepsy program on a full clinical hold.

regulatory action
90%
bullishMay 7

Formal closure of DOJ and SEC investigations into the company.

regulatory action
60%
bullishMay 7

Significant reduction in R&D and G&A expenses following the phase-out of the Alzheimer's program.

margin expansion
70%
bearishMay 7

FDA placed the lead TSC-related epilepsy program on a full clinical hold.

regulatory action
90%
bullishMay 7

Formal closure of DOJ and SEC investigations into the company.

regulatory action
60%
bullishMay 7

Significant reduction in R&D and G&A expenses following the phase-out of the Alzheimer's program.

margin expansion
70%
bearishMay 7

FDA placed the lead TSC-related epilepsy program on a full clinical hold.

regulatory action
90%
bullishMay 7

Formal closure of DOJ and SEC investigations into the company.

regulatory action
60%
bullishMay 7

Significant reduction in R&D and G&A expenses following the phase-out of the Alzheimer's program.

margin expansion
70%
bearishMay 7

FDA placed the lead TSC-related epilepsy program on a full clinical hold.

regulatory action
90%
bullishMay 7

Formal closure of DOJ and SEC investigations into the company.

regulatory action
60%
bullishMay 7

Significant reduction in R&D and G&A expenses following the phase-out of the Alzheimer's program.

margin expansion
70%
bearishMay 7

FDA placed the lead TSC-related epilepsy program on a full clinical hold.

regulatory action
90%
bullishMay 7

Formal closure of DOJ and SEC investigations into the company.

regulatory action
60%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing reveals a company in a high-stakes transition. Filana has successfully cleared the decks of its previous regulatory baggage and the financial weight of its failed Alzheimer's program, but it now faces a critical binary event: the lifting of the FDA clinical hold for its TSC-related epilepsy program. The financial results show a company that is effectively 'hibernating'—reducing costs to survive until it can restart clinical trials. For investors, the trade-off is clear. The downside is a continued burn of cash and potential dilution while waiting for regulatory clearance that may never come or may be delayed further. The upside is a first-in-class therapeutic for a significant unmet need in epilepsy. The synthesis of this filing suggests that while the operational 'cleanup' is complete, the fundamental value of the company now rests entirely on the FDA's willingness to allow simufilam to proceed into human trials for TSC.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.